https://scholars.lib.ntu.edu.tw/handle/123456789/551136
標題: | Young chronic hepatitis b patients with nucleos(t)ide analogue-induced hepatitis b e antigen seroconversion have a higher risk of HBV reactivation | 作者: | TAI-CHUNG TSENG CHUN-JEN LIU TUNG-HUNG SU HUNG-CHIH YANG Wang C.-C CHI-LING CHEN Kuo S.F.-T CHEN-HUA LIU PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2012 | 出版社: | Oxford University Press | 卷: | 206 | 期: | 10 | 起(迄)頁: | 1521-1531 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. It is unclear whether hepatitis B e antigen (HBeAg) seroconversion induced by nucleos(t)ide analogues (NUC) has a prognosis that is similar to that of spontaneous HBeAg seroconversion.Methods.A total of 148 noncirrhotic NUC-induced HBeAg seroconverters were consecutively enrolled. A historical control of 407 noncirrhotic spontaneous HBeAg seroconverters was also recruited. We compared the rates of HBeAg seroreversion and HBV reactivation between these 2 cohorts.Results.There were 1652.8 and 465.2 person-years of follow-up for spontaneous and NUC-induced HBeAg seroconverters, respectively. Compared with NUC-induced seroconverters, spontaneous seroconverters were younger when achieving HBeAg seroconversion. We thus compared these 2 cohorts according to their age at HBeAg seroconversion. In patients achieving HBeAg seroconversion before 30 years of age, NUC-induced seroconverters had a higher 2-year HBeAg seroreversion rate than spontaneous seroconverters (12.0 vs 2.9; P =. 004) and were at a higher risk of HBV reactivation (hazard ratio, 4.6; 95 confidence interval, 1.5-14.4). Using multivariate analysis, NUC-induced HBeAg seroconversion remained a risk factor of both endpoints in young HBeAg seroconverters.Conclusion.NUC-induced HBeAg seroconverters may not have durable response after stopping therapy. For patients achieving HBeAg seroconversion before 30 years of age, the risk of HBeAg seroreversion and HBV reactivation is higher in NUC-induced seroconverters than spontaneous HBeAg seroconverters. ? 2012 The Author. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983726125&doi=10.1093%2finfdis%2fjis569&partnerID=40&md5=ee593b8731223d662097155101c53ae9 https://scholars.lib.ntu.edu.tw/handle/123456789/551136 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jis569 | SDG/關鍵字: | adefovir; alanine aminotransferase; entecavir; hepatitis B(e) antigen; lamivudine; nucleoside analog; tenofovir; adult; age distribution; alanine aminotransferase blood level; article; cohort analysis; controlled study; drug efficacy; drug safety; female; genotype; hepatitis B; Hepatitis B virus; human; incidence; major clinical study; male; priority journal; real time polymerase chain reaction; seroconversion; treatment duration; treatment response; virus reactivation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。